9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2023
NA ElSayed, G Aleppo, VR Aroda, RR Bannuru… - Diabetes …, 2023 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …
ADA's current clinical practice recommendations and is intended to provide the components …
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2019
American Diabetes Association - Diabetes care, 2019 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
ADA's current clinical practice recommendations and is intended to provide the components …
ADA's current clinical practice recommendations and is intended to provide the components …
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2021
American Diabetes Association - Diabetes care, 2021 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
the ADA's current clinical practice recommendations and is intended to provide the …
the ADA's current clinical practice recommendations and is intended to provide the …
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020
American Diabetes Association - Diabetes care, 2020 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
the ADA's current clinical practice recommendations and is intended to provide the …
the ADA's current clinical practice recommendations and is intended to provide the …
9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2022
American Diabetes Association Professional … - Diabetes …, 2022 - Am Diabetes Assoc
The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
the ADA's current clinical practice recommendations and is intended to provide the …
the ADA's current clinical practice recommendations and is intended to provide the …
Pharmacologic approaches to glycemic treatment of type 2 diabetes: synopsis of the 2020 American diabetes association's standards of medical care in diabetes …
K Doyle-Delgado, JJ Chamberlain… - Annals of internal …, 2020 - acpjournals.org
Description: The American Diabetes Association (ADA) updates the Standards of Medical
Care in Diabetes annually to provide clinicians, patients, researchers, payers, and other …
Care in Diabetes annually to provide clinicians, patients, researchers, payers, and other …
New insulin glargine 300 U/ml compared with glargine 100 U/ml in insulin‐naive people with type 2 diabetes on oral glucose‐lowering drugs: a randomized controlled …
GB Bolli, MC Riddle, RM Bergenstal… - Diabetes, Obesity …, 2015 - Wiley Online Library
Aims To compare the efficacy and safety of new insulin glargine 300 U/ml (Gla‐300) with
that of glargine 100 U/ml (Gla‐100) in insulin‐naïve people with type 2 diabetes using oral …
that of glargine 100 U/ml (Gla‐100) in insulin‐naïve people with type 2 diabetes using oral …
Benefits of LixiLan, a titratable fixed-ratio combination of insulin glargine plus lixisenatide, versus insulin glargine and lixisenatide monocomponents in type 2 diabetes …
OBJECTIVE To evaluate efficacy and safety of LixiLan (iGlarLixi), a novel titratable fixed-
ratio combination of insulin glargine (iGlar) and lixisenatide (Lixi), compared with both …
ratio combination of insulin glargine (iGlar) and lixisenatide (Lixi), compared with both …
[HTML][HTML] Three-year efficacy of complex insulin regimens in type 2 diabetes
Background Evidence supporting the addition of specific insulin regimens to oral therapy in
patients with type 2 diabetes mellitus is limited. Methods In this 3-year open-label …
patients with type 2 diabetes mellitus is limited. Methods In this 3-year open-label …
Use of twice-daily exenatide in basal insulin–treated patients with type 2 diabetes: a randomized, controlled trial
Background: Insulin replacement in diabetes often requires prandial intervention to reach
hemoglobin A1c (HbA1c) targets. Objective: To test whether twice-daily exenatide injections …
hemoglobin A1c (HbA1c) targets. Objective: To test whether twice-daily exenatide injections …